Good morning :)
$
₹
Scilex Holding Company

Scilex Holding Company

SCLX

NASDAQ
Asset Logo

Scilex Holding Company

SCLX

NASDAQ
$2.330.72% (-0.01)
$
₹
$2.330.72% (-0.01)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - General

Micro Cap

With a market cap of $16.5M the stock is ranked 5514

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

28.85
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-49.7
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 1 analyst's reports

Buy
0 analyst
Hold
1 analyst
Sell
0 analyst

Price Upside

+20751.09%

Earnings Growth

+97.18%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
42.74
42.74
1Y Return
55.33%
55.33%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
40.03
40.03
1Y Return
37.93%
37.93%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
115.29
115.29
1Y Return
66.63%
66.63%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
22.82
22.82
1Y Return
14.79%
14.79%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
25.78
25.78
1Y Return
1.93%
1.93%
Buy Reco %
83.33
83.33
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 20751.09% growth, versus a trailing 3-year CAGR of -66.01%.

2026
Current$2.35Baseline
Analyst Target - 1 year
Target$490+20751.09%

All values in $

202220232024202520262027$136.34$270.56$404.78Target+20751.09%
2026
Current$2.35Baseline
Analyst Target - 1 year
Target$490+20751.09%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-31.61Baseline
Forecast for Dec 2026
High$-0.89+97.18%
Average$-0.89+97.18%
Low$-0.89+97.18%

All values in $

2021202220232024202520262.77-0.07-29.06-20.25-31.61Low+97.18%Average+97.18%High+97.18%
2025
Current$-31.61Baseline
Forecast for Dec 2026
High$-0.89+97.18%
Average$-0.89+97.18%
Low$-0.89+97.18%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

10.5
-257.2
4.7
-33.1
8.6
-43.2
7.6
-113.5
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue10.8816.3714.4314.959.8910.564.798.617.64
Net Income-24.37-37.58-4.38-6.46-26.08-86.06-257.23-33.11-43.27-113.5
Net Profit Margin-223.97%-229.57%-30.39%-43.35%-521.18%-869.65%-2435.92%-690.84%-502.38%-1485.21%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - General

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Scilex Holding Company -28.85-
Eli Lilly and Company42.7430.781.15
Johnson & Johnson40.037.632.82
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare SCLX with any stock or ETF
Compare SCLX with any stock or ETF
Comparing from
SCLX
LLY
JNJ
Loading...

Frequently asked questions

  1. Scilex Holding Company (SCLX) share price today is $2.33 as of October 27, 2026 at 1:29 AM IST. The stock touched a day high of $2.45 and a day low of $2.28.

  2. Scilex Holding Company stock trades on NASDAQ under the ticker symbol SCLX.

  3. Scilex Holding Company's market capitalization is $16.53M as of October 27, 2026 at 1:29 AM IST.

  4. Scilex Holding Company's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Scilex Holding Company's price-to-book (P/B) ratio is 28.85 as of October 26, 2026.

  6. Yes, You can buy Scilex Holding Company shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Scilex Holding Company shares in three steps: 1. Search Scilex Holding Company on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Scilex Holding Company trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Scilex Holding Company (SCLX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 4.2863 shares at the current price of $2.33.

Loading...